Scholar Rock Holding Corporation (SRRK) News
Filter SRRK News Items
SRRK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SRRK News Highlights
- For SRRK, its 30 day story count is now at 10.
- Over the past 26 days, the trend for SRRK's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ROCK, MG and AGE are the most mentioned tickers in articles about SRRK.
Latest SRRK News From Around the Web
Below are the latest news stories about Scholar Rock Holding Corp that investors may wish to consider to help them evaluate SRRK as an investment opportunity.
Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual MeetingScholar Rock today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 from April 10 - 15. |
Why Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular AtrophyScholar Rock (NASDAQ: SRRK) shares dropped despite the company reporting positive 12-month data on spinal muscular atrophy (SMA) candidate apitegromab. The 12-month update was broadly in line with the six-month data that was announced in October last year. Most effects observed at six months have proven to be durable at 12 months. In some cases, the efficacy results improved between the six and 12-month readouts. A cohort of children with type 2 SMA aged two years and older who began treatment with Biogen Inc (NASDAQ: BIIB) / Ionis Pharmaceuticals Inc’s (NASDAQ: IONS) Spinraza (nusinersen) before turning five years old showed a mean improvement of 7.1 points on a motor scale after receiving 20-mg/kg infusions of apitegromab on top of their existing therapy. In the 2 mg/kg dose arm, an i... |
Scholar Rock Reports Apitegromab Data In Spinal Muscular AtrophyScholar Rock (NASDAQ: SRRK) has announced top-line data from the TOPAZ Phase 2 trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). In Cohort 1 (pooled population), the mean change from baseline in Revised Hammersmith Scale (RHS) score was a 0.3-point decline. RHS is an assessment of the physical abilities of SMA patients. Patients in this cohort were treated with apitegromab either as a monotherapy or in conjunction with an approved SMN upregulator therapy (nusinersen). 57% of patients observed maintenance or improvement in RHS score, and 22% of patients achieved at least a 3-point increase in RHS score from baseline. Cohort 2 included patients who were already receiving nusinersen treatment initiated at age five years or older. Effic... |
Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced positive top-line data from the TOPAZ Phase 2 clinical trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). |
Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of ToxicologyCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the publication of preclinical development data for SRK-181 in the peer-reviewed journal International Journal of Toxicology. |
Scholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscular AtrophyCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced issuance of U.S. patent protecting add-on or combination therapy with a myostatin inhibitor for spinal muscular atrophy (SMA). |
Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific ConferenceScholar Rock announced its oral and poster presentations at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference |
Scholar Rock Reports Full Year 2020 Financial Results and Highlights Business ProgressCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the full year ended December 31, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs. “2021 is poised to further validate the therapeutic potential of our scientific platform, and we are starting the year with strong m |
Analysts Estimate Scholar Rock Holding Corporation (SRRK) to Report a Decline in Earnings: What to Look Out forScholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Scholar Rock Announces Senior Management PromotionsCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary, and George Nomikos, M.D., Ph.D. to Senior Vice President, |